Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessCompaniesRanbaxy shares end down 7% as Mylan sues FDA to block Lipitor launch

    Ranbaxy shares end down 7% as Mylan sues FDA to block Lipitor launch

    Ranbaxy shares plunged 7% to close at Rs 435.95 Monday after US company Mylan Inc sued the US Foods and Drug Administration for an injunction on the launch of Ranbaxy’s cholesterol treatment drug, Atorvastatin, which is a generic version of Pfizer’s Lipitor.

    March 21, 2011 / 18:45 IST

    Ranbaxy shares plunged 7% to close at Rs 435.95 Monday after US company Mylan Inc sued the US Foods and Drug Administration for an injunction on the launch of Ranbaxy

    first published: Mar 21, 2011 06:30 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347